Logo image of HIVE

HIVE DIGITAL TECHNOLOGIES LT (HIVE) Stock Fundamental Analysis

NASDAQ:HIVE - Nasdaq - CA4339211035 - Common Stock - Currency: USD

2.255  +0 (+0.22%)

Fundamental Rating

4

HIVE gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 283 industry peers in the Software industry. The financial health of HIVE is average, but there are quite some concerns on its profitability. HIVE is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year HIVE has reported negative net income.
HIVE had a positive operating cash flow in the past year.
In multiple years HIVE reported negative net income over the last 5 years.
Each year in the past 5 years HIVE had a positive operating cash flow.
HIVE Yearly Net Income VS EBIT VS OCF VS FCFHIVE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M

1.2 Ratios

The Return On Assets of HIVE (-0.56%) is better than 60.07% of its industry peers.
With a decent Return On Equity value of -0.67%, HIVE is doing good in the industry, outperforming 62.19% of the companies in the same industry.
Industry RankSector Rank
ROA -0.56%
ROE -0.67%
ROIC N/A
ROA(3y)-37.49%
ROA(5y)-16.27%
ROE(3y)-49.77%
ROE(5y)-22%
ROIC(3y)N/A
ROIC(5y)N/A
HIVE Yearly ROA, ROE, ROICHIVE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

1.3 Margins

HIVE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HIVE Yearly Profit, Operating, Gross MarginsHIVE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

More info and screens

6

2. Health

2.1 Basic Checks

HIVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HIVE has more shares outstanding
The number of shares outstanding for HIVE has been increased compared to 5 years ago.
The debt/assets ratio for HIVE has been reduced compared to a year ago.
HIVE Yearly Shares OutstandingHIVE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
HIVE Yearly Total Debt VS Total AssetsHIVE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

HIVE has an Altman-Z score of 3.18. This indicates that HIVE is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.18, HIVE is in the better half of the industry, outperforming 60.42% of the companies in the same industry.
A Debt/Equity ratio of 0.04 indicates that HIVE is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.04, HIVE is in line with its industry, outperforming 58.30% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 3.18
ROIC/WACCN/A
WACC10.47%
HIVE Yearly LT Debt VS Equity VS FCFHIVE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M 400M

2.3 Liquidity

HIVE has a Current Ratio of 3.72. This indicates that HIVE is financially healthy and has no problem in meeting its short term obligations.
HIVE has a better Current ratio (3.72) than 80.92% of its industry peers.
HIVE has a Quick Ratio of 3.72. This indicates that HIVE is financially healthy and has no problem in meeting its short term obligations.
HIVE has a Quick ratio of 3.72. This is amongst the best in the industry. HIVE outperforms 80.92% of its industry peers.
Industry RankSector Rank
Current Ratio 3.72
Quick Ratio 3.72
HIVE Yearly Current Assets VS Current LiabilitesHIVE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

7

3. Growth

3.1 Past

HIVE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.27%, which is quite impressive.
The Revenue has been growing slightly by 0.71% in the past year.
HIVE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.59% yearly.
EPS 1Y (TTM)96.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
Revenue 1Y (TTM)0.71%
Revenue growth 3Y-18.07%
Revenue growth 5Y31.59%
Sales Q2Q%-15.51%

3.2 Future

The Earnings Per Share is expected to grow by 387.80% on average over the next years. This is a very strong growth
Based on estimates for the next years, HIVE will show a very strong growth in Revenue. The Revenue will grow by 53.13% on average per year.
EPS Next Y241.77%
EPS Next 2Y387.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year161.89%
Revenue Next 2Y105.09%
Revenue Next 3Y53.13%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HIVE Yearly Revenue VS EstimatesHIVE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M
HIVE Yearly EPS VS EstimatesHIVE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

HIVE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 83.71, which means the current valuation is very expensive for HIVE.
HIVE's Price/Forward Earnings is on the same level as the industry average.
HIVE's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 35.31.
Industry RankSector Rank
PE N/A
Fwd PE 83.71
HIVE Price Earnings VS Forward Price EarningsHIVE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HIVE Per share dataHIVE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

HIVE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as HIVE's earnings are expected to grow with 387.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y387.8%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HIVE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HIVE DIGITAL TECHNOLOGIES LT

NASDAQ:HIVE (8/15/2025, 3:09:06 PM)

2.255

+0 (+0.22%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)08-11 2025-08-11
Earnings (Next)N/A N/A
Inst Owners17.39%
Inst Owner Change-3.61%
Ins Owners0.28%
Ins Owner Change0%
Market Cap509.20M
Analysts80
Price Target4.31 (91.13%)
Short Float %4.6%
Short Ratio0.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)105.17%
Min EPS beat(2)100.9%
Max EPS beat(2)109.43%
EPS beat(4)4
Avg EPS beat(4)75.57%
Min EPS beat(4)43.42%
Max EPS beat(4)109.43%
EPS beat(8)6
Avg EPS beat(8)50.65%
EPS beat(12)8
Avg EPS beat(12)-137.95%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.3%
Min Revenue beat(2)-1.52%
Max Revenue beat(2)6.13%
Revenue beat(4)2
Avg Revenue beat(4)3.4%
Min Revenue beat(4)-8.08%
Max Revenue beat(4)17.08%
Revenue beat(8)5
Avg Revenue beat(8)3.72%
Revenue beat(12)8
Avg Revenue beat(12)17.33%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.75%
PT rev (3m)-16.22%
EPS NQ rev (1m)-57.49%
EPS NQ rev (3m)-36.95%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-1.3%
Revenue NQ rev (3m)-13.09%
Revenue NY rev (1m)-0.93%
Revenue NY rev (3m)-0.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 83.71
P/S 4.42
P/FCF N/A
P/OCF 30.61
P/B 1.13
P/tB 1.13
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)0.03
Fwd EY1.19%
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)0.07
OCFY3.27%
SpS0.51
BVpS1.99
TBVpS1.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.56%
ROE -0.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.49%
ROA(5y)-16.27%
ROE(3y)-49.77%
ROE(5y)-22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 187.21%
Cap/Sales 104.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.72
Quick Ratio 3.72
Altman-Z 3.18
F-Score4
WACC10.47%
ROIC/WACCN/A
Cap/Depr(3y)97.27%
Cap/Depr(5y)157.57%
Cap/Sales(3y)54.64%
Cap/Sales(5y)58.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
EPS Next Y241.77%
EPS Next 2Y387.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.71%
Revenue growth 3Y-18.07%
Revenue growth 5Y31.59%
Sales Q2Q%-15.51%
Revenue Next Year161.89%
Revenue Next 2Y105.09%
Revenue Next 3Y53.13%
Revenue Next 5YN/A
EBIT growth 1Y-44.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year280.42%
EBIT Next 3Y69.4%
EBIT Next 5YN/A
FCF growth 1Y-93.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.55%
OCF growth 3Y-36.92%
OCF growth 5Y84.91%